BIOSYNGEN PTE. LTD. Mediaroom

Biosyngen Best-in-Class Next-Generation Tumor-Infiltrating Lymphocyte (TIL) Technology Debuts on ESMO 2024 Annual Meeting

BARCELONA, Spain, Sept. 20, 2024 /PRNewswire/ -- The highly anticipated 2024 European Society for M...

2024-09-20 20:30 1446

Biosyngen Best-in-Class Next-Generation Tumor-Infiltrating Lymphocyte (TIL) Technology Debuts on ESMO 2024 Annual Meeting

Biosyngen Presents Pioneering"Conditional Activation + Armor Enhancement" SUPER-T technology at ESMO 2024

BARCELONA, Spain, Sept. 19, 2024 /PRNewswire/ -- The highly anticipated 2024 European Society for M...

2024-09-19 20:30 1083

Biosyngen's first-in-class CAR-T asset targeting solid tumors has entered pivotal phase II trial, Phase I trial data debut at ESMO 2024 Annual Congress

BARCELONA, Spain, Sept. 18, 2024 /PRNewswire/ -- The highly anticipated 2024 European Society for M...

2024-09-18 18:18 1412

Biosyngen's first-in-class CAR-T asset targeting solid tumors has entered pivotal phase II trial, Phase I trial data debut at ESMO 2024 Annual Congress

Biosyngen's BRG01 Receives FDA Approval for Phase II Clinical Trial

SINGAPORE, Aug. 13, 2024 /PRNewswire/ -- Biosyngen is proud to announce that the U.S. Food and Drug...

2024-08-13 09:00 1782

Biosyngen Partners with Singapore's Agency for Science, Technology and Research (A*STAR) to Advance Autoimmune Therapy

GUANGZHOU, China, Aug. 1, 2024 /PRNewswire/ -- Biosyngen has announced a strategic collaboration wi...

2024-08-01 16:01 2200

Biosyngen Partners with Singapore's Agency for Science, Technology and Research (A*STAR) to Advance Autoimmune Therapy

Biosyngen's BRG01 enters Phase II clinical trial, a first-in-kind autologous EBV-Specific CAR-T Therapy for Solid Tumors on Recurrent/Metastatic Nasopharyngeal Carcinoma

SINGAPORE, July 16, 2024 /PRNewswire/ -- Biosyngen, a leading biotechnology company focused on the ...

2024-07-16 19:29 2121

Biosyngen's BRG01 enters Phase II clinical trial, a first-in-kind autologous EBV-Specific CAR-T Therapy for Solid Tumors on Recurrent/Metastatic Nasopharyngeal Carcinoma

SINGAPORE, July 16, 2024 /PRNewswire/ -- Biosyngen, a leading biotechnology company focused on the ...

2024-07-16 17:10 2325

Biosyngen Announces FDA Fast Track Designation for BST02 in Treatment of Liver Cancer

SINGAPORE, Feb. 1, 2024 /PRNewswire/ -- Biosyngen is proud to announce that its latest groundbreaki...

2024-02-01 17:41 2349

Biosyngen Announces FDA Fast Track Designation for BST02 in Treatment of Liver Cancer

Biosyngen's BST02, the World's First TIL Therapy for Liver Cancer, is Granted an IND Approval by FDA

SINGAPORE, Oct. 26, 2023 /PRNewswire/ -- On October 26, 2023, Biosyngen's TIL therapy BST02 for liv...

2023-10-26 18:18 2611

Biosyngen's BST02, the World's First TIL Therapy for Liver Cancer, is Granted an IND Approval by FDA

Biosyngen received the Asia Pacific Cell & Gene Therapy Excellence Awards (APCGTEA) 2023

SINGAPORE, Sept. 18, 2023 /PRNewswire/ -- On September 14, 2023, Biosyngen Pte Ltd (hereinafter ref...

2023-09-18 17:53 2202

Biosyngen received the Asia Pacific Cell & Gene Therapy Excellence Awards (APCGTEA) 2023

Biosyngen received FDA approval for Phase I/II Clinical Trials for BRL03, targeting Lung Cancer, Gastric Cancer and other advanced Solid Tumors

SINGAPORE, Sept. 11, 2023 /PRNewswire/ -- On September 9th, 2023, Biosyngen Pte Ltd (hereafter as "...

2023-09-11 14:53 1466

Biosyngen received FDA approval for Phase I/II Clinical Trials for BRL03, targeting Lung Cancer, Gastric Cancer and other advanced Solid Tumors

Biosyngen's First-in-class Cell Therapy BRG01 Receives FDA Fast Track Designation

SINGAPORE, July 12, 2023 /PRNewswire/ -- On July 6, 2023, Biosyngen received an official notificati...

2023-07-12 13:38 3456

Creating the China-Singapore Translational Medicine Center - Biosyngen's pursuit to be a leading player in the CGT industry globally hits new milestone.

SINGAPORE, July 12, 2023 /PRNewswire/ -- This is a model of cooperation between Singapore and China...

2023-07-12 10:32 3224

Latest News

Biosyngen Best-in-Class Next-Generation Tumor-Infiltrating Lymphocyte (TIL) Technology Debuts on ESMO 2024 Annual Meeting

Biosyngen Presents Pioneering"Conditional Activation + Armor Enhancement" SUPER-T technology at ESMO 2024

Biosyngen's first-in-class CAR-T asset targeting solid tumors has entered pivotal phase II trial, Phase I trial data debut at ESMO 2024 Annual Congress

Biosyngen's BRG01 Receives FDA Approval for Phase II Clinical Trial

Biosyngen Partners with Singapore's Agency for Science, Technology and Research (A*STAR) to Advance Autoimmune Therapy

Biosyngen's BRG01 enters Phase II clinical trial, a first-in-kind autologous EBV-Specific CAR-T Therapy for Solid Tumors on Recurrent/Metastatic Nasopharyngeal Carcinoma

Biosyngen's BRG01 enters Phase II clinical trial, a first-in-kind autologous EBV-Specific CAR-T Therapy for Solid Tumors on Recurrent/Metastatic Nasopharyngeal Carcinoma

Biosyngen Announces FDA Fast Track Designation for BST02 in Treatment of Liver Cancer

Biosyngen's BST02, the World's First TIL Therapy for Liver Cancer, is Granted an IND Approval by FDA

Biosyngen received the Asia Pacific Cell & Gene Therapy Excellence Awards (APCGTEA) 2023

Biosyngen received FDA approval for Phase I/II Clinical Trials for BRL03, targeting Lung Cancer, Gastric Cancer and other advanced Solid Tumors

Biosyngen's First-in-class Cell Therapy BRG01 Receives FDA Fast Track Designation

Creating the China-Singapore Translational Medicine Center - Biosyngen's pursuit to be a leading player in the CGT industry globally hits new milestone.

Immuno-oncology company Biosyngen opens new cell therapy GMP facility in Singapore

Biosyngen's Cell Therapy BRG01 Granted Orphan Drug Designation by the U.S. FDA for Treatment of Nasopharyngeal Cancer

Biosyngen announces FDA IND approval of its second product for EBV-positive lymphoma

Biosyngen received China NMPA IND approval for its T-cell redirection therapy targeting EBV-positive Lymphoma

PM Lee receives a first-hand update by Biosyngen on its progress in cell therapy

Biosyngen has obtained FDA IND clearance of BRG01 for Phase I/II clinical trials against Nasopharyngeal Cancer

IND Application of Biosyngen's Cell Therapy (BRG01) for Nasopharyngeal Cancer Approved by China NMPA